中国组织工程研究 ›› 2024, Vol. 28 ›› Issue (19): 3097-3103.doi: 10.12307/2024.152

• 干细胞综述 stem cell review • 上一篇    下一篇

提高间充质干细胞治疗皮瓣缺血再灌注损伤的策略

何  波1,何志军2,李金鹏2,刘  涛2,马岁录1,魏晓涛1,王威威1,谢  婧1   

  1. 1甘肃中医药大学,甘肃省兰州市   730030;2甘肃省中医院,甘肃省兰州市   730050
  • 收稿日期:2023-01-28 接受日期:2023-05-19 出版日期:2024-07-08 发布日期:2023-09-26
  • 通讯作者: 何志军,教授,主任医师,硕士生导师,甘肃省中医院,甘肃省兰州市 730050 李金鹏,副主任医师,硕士,甘肃省中医院,甘肃省兰州市 730050
  • 作者简介:何波,1991年生,甘肃中医药大学在读硕士,主要从事中医药防治骨与软组织疾病、皮瓣移植等方面研究。
  • 基金资助:
    国家自然科学基金(81660802),项目负责人:何志军;甘肃省中医药项目(GZKZ-2020-2),项目负责人:何志军

Improving the strategy of mesenchymal stem cells in treatment of flap ischemia-reperfusion injury

He Bo1, He Zhijun2, Li Jinpeng2, Liu Tao2, Ma Suilu1, Wei Xiaotao1, Wang Weiwei1, Xie Jing1   

  1. 1Gansu University of Chinese Medicine, Lanzhou 730030, Gansu Province, China; 2Gansu Provincial Hospital of TCM, Lanzhou 730050, Gansu Province, China
  • Received:2023-01-28 Accepted:2023-05-19 Online:2024-07-08 Published:2023-09-26
  • Contact: He Zhijun, Professor, Chief physician, Master’s supervisor, Gansu Provincial Hospital of TCM, Lanzhou 730050, Gansu Province, China Li Jinpeng, Associate chief physician, Master, Gansu Provincial Hospital of TCM, Lanzhou 730050, Gansu Province, China
  • About author:He Bo, Master candidate, Gansu University of Chinese Medicine, Lanzhou 730030, Gansu Province, China
  • Supported by:
    National Natural Science Foundation of China, No. 81660802 (to HZJ); Gansu Province Traditional Chinese Medicine Project, No. GZKZ-2020-2 (to HZJ)

摘要:


文题释义:

间充质干细胞:是一类起源于中胚层的成体干细胞,也是一种多能干细胞,具有归巢特性、分化能力和免疫调节等作用。
皮瓣缺血再灌注损伤:是指发生过长时间缺血的皮瓣组织在血流重新灌注后,组织的功能不但没有改善,反而加重,最终导致皮瓣坏死的现象。


背景:间充质干细胞在治疗皮瓣缺血再灌注损伤方面潜力巨大,然而其自身的缺陷及在治疗皮瓣缺血再灌注损伤中的作用下降等原因限制了其广泛应用。

目的:综述提高间充质干细胞治疗皮瓣缺血再灌注损伤的策略,为其进一步理论研究和临床应用提供参考。 
方法:检索中国知网、万方和PubMed 数据库收录的相关文献。中文检索词为“间充质干细胞,皮瓣缺血再灌注损伤,间充质基质细胞,干细胞,皮瓣,缺血再灌注损伤,预处理,基因修饰,生物材料封装,联合运用”。英文检索词为“mesenchymal stem cell,Ischemia-reperfusion injury of skin flap,Mesenchymal stromal cells,Stem cells,skin flap,Ischemia-reperfusion injury,Pretreatment,Gene modification,Biomaterial packaging,Joint application”。检索2007年以来发表的相关文献,通过阅读文章剔除研究内容与文章主题关系不大、质量较差及内容陈旧的文献,最终纳入75篇文献进行归纳总结。 

结果与结论:①间充质干细胞具有抑制炎症反应、抗氧化应激以及诱导血管新生等显著作用,在治疗皮瓣缺血再灌注损伤中蕴含着巨大潜力。②尽管间充质干细胞在治疗皮瓣缺血再灌注损伤中显示出了巨大潜力,但其在治疗上存在的缺陷限制了在临床上的广泛运用,通过预处理(细胞因子、低氧、药物及其他预处理间充质干细胞)、基因修饰间充质干细胞、生物材料封装间充质干细胞以及间充质干细胞和其他药物或治疗方法联合运用等,这些方法不仅可以克服间充质干细胞在治疗上的缺陷,还提高了其在皮瓣缺血再灌注损伤方面的治疗效果。③因此,在未来进一步提高间充质干细胞治疗皮瓣缺血再灌注损伤的效果,挖掘其治疗潜力,对于间充质干细胞的研究和皮瓣缺血再灌注损伤的治疗都具有非常重要的意义。

https://orcid.org/0000-0003-2787-0033 (何波) 

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

关键词: 间充质干细胞, 干细胞, 皮瓣, 缺血再灌注损伤, 预处理, 基因修饰, 生物材料封装, 联合运用

Abstract: BACKGROUND: Mesenchymal stem cells have great potential in the treatment of ischemia-reperfusion injury of skin flaps. However, their defects and the decline of their role in the treatment of ischemia-reperfusion injury of skin flaps restrict their wide application.
OBJECTIVE: To review the strategies for improving the treatment of ischemia-reperfusion injury of skin flaps with mesenchymal stem cells, and provide a reference for its further theoretical research and clinical application. 
METHODS: Relevant documents included in CNKI, WanFang and PubMed were searched. The Chinese and English search terms were “mesenchymal stem cell, ischemia-reperfusion adjustment of skin flap, mesenchymal stem cells, stem cells, skin flap, ischemia-reperfusion injury, pretreatment, gene modification, biomaterial packaging, joint application”. The relevant documents since 2007 were retrieved, and the documents with little relationship between the research content and the article theme, poor quality and outdated content were eliminated through reading the article, and finally 75 documents were included for summary.
RESULTS AND CONCLUSION: (1) Mesenchymal stem cells can inhibit inflammatory reactions, resist oxidative stress and induce angiogenesis, which has great potential in the treatment of skin flap ischemia-reperfusion injury. (2) Although mesenchymal stem cells have shown great potential in the treatment of skin flap ischemia-reperfusion injury, their shortcomings in treatment have limited their widespread clinical application. Through pre-treatment (cytokines, hypoxia, drugs, and other pre-treatment mesenchymal stem cells), gene-modified mesenchymal stem cells, biomaterial encapsulation of mesenchymal stem cells, as well as the combined use of mesenchymal stem cells and other drugs or therapeutic methods, can not only overcome the shortcomings of mesenchymal stem cells in treatment, but also improve their therapeutic effectiveness in skin flap ischemia-reperfusion injury. (3) Therefore, further improving the effectiveness of mesenchymal stem cells in treating skin flap ischemia-reperfusion injury and exploring its therapeutic potential are of great significance for the research of mesenchymal stem cells and the treatment of skin flap ischemia-reperfusion injury.

Key words: mesenchymal stem cell, stem cell, skin flap, ischemia-reperfusion injury, pretreatment, gene modification, biomaterial packaging, joint application

中图分类号: